Evan Y. Yu, MD

Articles

Addressing Unmet Needs in Nonmetastatic CRPC

July 26th 2022

Before closing out their second module, panelists highlight remaining unmet needs in the setting of nonmetastatic castration-resistant prostate cancer.

Selecting Among Available AR Inhibitors in Nonmetastatic CPRC

July 26th 2022

A comprehensive discussion on factors that inform treatment selection of available AR-targeted therapy for patients with nonmetastatic CRPC.

Optimizing Management of nmCRPC: Patient Monitoring and Initiating Therapy

July 19th 2022

Expert perspectives on monitoring patients with nonmetastatic castration-resistant prostate cancer and deciding when to initiate systemic therapy.

Clinical Scenario 2: A 64-Year-Old Man With nmCRPC

July 19th 2022

Shared insight on a clinical scenario of a patient with nonmetastatic castration-resistant prostate cancer who was treated with prostatectomy and adjuvant therapy.

Improving Patient Monitoring in the Setting of Metastatic HSPC

July 12th 2022

Closing out their discussion on a clinical scenario of metastatic HSPC, expert panelists consider optimal patient monitoring strategies and novel imaging.

Clinical Trial Data in Metastatic HSPC From the ASCO 2022 Annual Meeting

July 12th 2022

Expert panelists briefly share their excitement for trial data readouts in metastatic hormone-sensitive prostate cancer from the annual ASCO 2022 Annual meeting.

Establishing Eligibility for Frontline AR-Targeted Therapy in mHSPC

July 5th 2022

Continuing their discussion on frontline AR-targeted therapy in mHSPC, experts define how accessibility and patient eligibility impact treatment selection.

Factors in Selecting AR-Targeted Therapy for Patients With Metastatic HSPC

July 5th 2022

Expert perspectives on frontline AR-targeted therapy in metastatic hormone-sensitive prostate cancer, with deference to recent clinical trial data on triplet therapy.

Optimizing Management of mHSPC: Multimodality Care and Genetic Testing

June 28th 2022

A brief review of the respective roles of multidisciplinary care and genetic testing in patients diagnosed with metastatic hormone-sensitive prostate cancer.

Clinical Scenario 1: A 67-Year-Old With Metastatic HSPC

June 28th 2022

Centering discussion on a clinical scenario of metastatic hormone-sensitive prostate cancer, expert panelists consider how they might approach frontline therapy in this setting.

Prostate Cancer Management: Future Directions in Care

May 25th 2022

Closing out their discussion on the management of prostate cancer, panelists consider remaining unmet needs and future directions in care.

Results of the VISION Trial and Real-World Use of 177Lu-PSMA-617 in mCRPC

May 25th 2022

Reflections on results of the VISION trial, which utilized 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Addressing Bone and Visceral Metastases in Metastatic CRPC

May 18th 2022

A broader perspective on the management of bone and visceral metastases in metastatic CRPC given the current treatment landscape.

Role of 177Lu-PSMA-617 in mCRPC and Bone Metastases

May 18th 2022

Shifting their focus to 177Lu-PSMA-617 in metastatic CRPC, expert panelists consider its role in sequencing therapy and managing bone metastases.

Selecting Among Novel Imaging Options in Metastatic CRPC

May 11th 2022

A brief discussion on how to select and apply novel imaging strategies in patients with metastatic castration-resistant prostate cancer.

Metastatic CRPC: Utility of Imaging as a Biomarker

May 11th 2022

Shared insight on the role of imaging as a phenotypic biomarker in patients being treated for metastatic castration-resistant prostate cancer.

DNA Alterations and Selection of PARP Inhibitors in mCRPC

May 4th 2022

Expert perspectives on how DNA alterations may inform the selection and use of PARP inhibitors in metastatic CRPC.

Overview of Therapy for mCRPC: PARP Inhibitors

May 4th 2022

A broad overview of the armamentarium for metastatic CRPC followed by detailed discussion on the role of PARP inhibitors in this setting.

Interpreting Data From the ARASENS Trial in Metastatic HSPC

April 27th 2022

Comprehensive insight on results from the ARASENS trial and how panelists will be incorporating what was learned into real-world clinical practice.

Selecting Optimal Therapy for mHSPC: Design of the ARASENS Trial

April 27th 2022

Focusing on treatment selection factors in metastatic HSPC, panelists consider how the ARASENS trial redefined treatment approaches.